Novartis Acquires Amblyotech to Develop Digital Therapy for Amblyopia

Novartis Acquires Gyroscope Therapeutics

December 22, 2021

Biotechnology

Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.

SightMD Acquires Sambursky Eye & Esthetics

January 21, 2025

Healthcare Services

SightMD (via Sight Growth Partners) has acquired Sambursky Eye & Esthetics, integrating the long-established ophthalmology practice into its New York network. The deal expands SightMD's clinical footprint in the Southern Tier of New York and adds experienced cataract and LASIK surgeons and related surgical capabilities to the platform.

Thoma Bravo Invests in Bluesight to Support Bluesight's Acquisition of Medacist

July 17, 2023

Healthcare Services

Thoma Bravo made a strategic growth investment in Bluesight to support Bluesight's acquisition of Medacist, combining two medication-management and drug-diversion analytics businesses into a single hospital pharmacy software platform. The combined company will expand Bluesight's medication intelligence capabilities and serve more than 2,000 hospitals across North America; committed financing was led by Monroe Capital and existing investor New Leaf Ventures remains invested. Financial terms were not disclosed.

Natus Sensory Acquires TheraB Medical

February 11, 2026

Medical Devices

Natus Sensory has acquired TheraB Medical, a developer of the SnugLit wearable phototherapy swaddle for neonatal jaundice, following the product's FDA 510(k) clearance in January 2026. The acquisition expands Natus Sensory's newborn care portfolio by adding a portable, family-centered phototherapy option intended to broaden treatment settings and global access.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.